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BACKGROUND: Activating mutations of FGFR3 are frequently identified in superficial urothelial carcinoma (UC) and increased
expression of FGFR1 and FGFR3 are common in both superficial and invasive UC.
METHODS: The effects of inhibition of receptor activity by three small molecule inhibitors (PD173074, TKI-258 and SU5402) were
investigated in a panel of bladder tumour cell lines with known FGFR expression levels and FGFR3 mutation status.
RESULTS: All inhibitors prevented activation of FGFR3, and inhibited downstream MAPK pathway signalling. Response was related to
FGFR3 and/or FGFR1 expression levels. Cell lines with the highest levels of FGFR expression showed the greatest response and little
or no effect was measured in normal human urothelial cells or in UC cell lines with activating RAS gene mutations. In sensitive cell
lines, the drugs induced cell cycle arrest and/or apoptosis. IC50 values for PD173074 and TKI-258 were in the nanomolar
concentration range compared with micromolar concentrations for SU5402. PD173074 showed the greatest effects in vitro and
in vivo significantly delayed the growth of subcutaneous bladder tumour xenografts.
CONCLUSION: These results indicate that inhibition of FGFR1 and wild-type or mutant FGFR3 may represent a useful therapeutic
approach in patients with both non-muscle invasive and muscle invasive UC.
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Urothelial carcinoma (UC) of the bladder is the fifth most common
cancer in the developed world (Parkin et al, 2005) and can be divided
into two groups, distinct at both the clinical and molecular level
(Wu, 2005; Knowles, 2006). The first group, which at presentation
represents 450% of tumours, contains low-grade non-muscle
invasive, papillary lesions (stage pTa and pT1) (WHO, 2004).
Although this group has a high incidence of recurrence (B70%),
progression to muscle invasion is not common (10–20%) and
prognosis is good (90% survival at 5 years) (Holmang et al, 1995;
Kurth et al, 1995). Standard treatment involves complete endoscopic
resection of the tumour. However, residual malignant cells may
remain and patients must be monitored for recurrence by regular
cystoscopy, placing a huge burden on patients and health-care
providers. Consequently bladder cancer is the most expensive cancer
to treat (Sangar et al, 2005). For those tumours that are muscle
invasive at diagnosis (B20%) there is a much poorer prognosis with
o50% survival at 5 years (Stein et al,2 0 0 1 ) .T h e s ei n v a s i v et u m o u r s
frequently progress to life-threatening metastasis, which, once
clinically apparent, is associated with a 5-year survival rate of 6%.
The development of more effective therapies is required both to target
residual tumour cells to prevent local recurrence via intravesical
treatment of superficial UC and to provide more effective systemic
therapy for invasive and metastatic tumours.
FGFR3 is a member of a family of four highly conserved
transmembrane receptor kinases for the fibroblast growth factor
(FGF) family of ligands, which have key roles in the regulation of
cell proliferation, differentiation and tumorigenesis. Mutation of
FGFR3 is the most common genetic alteration in superficial UC
(Cappellen et al, 1999; Billerey et al, 2001; Sibley et al, 2001a), and
is strongly associated with low tumour grade and stage (Billerey
et al, 2001; Kimura et al, 2001; van Rhijn et al, 2001). Mutations
result in constitutive activation of the receptor (Ornitz and Itoh,
2001). FGFR3 protein expression is strongly related to mutation
status, with increased expression in the majority of FGFR3-mutant
superficial tumours (Tomlinson et al, 2007a). Increased FGFR3
signalling may also be achieved via overexpression of the wild-type
receptor and 440% of muscle invasive bladder tumours have been
found to overexpress wild-type FGFR3 protein (Tomlinson et al,
2007a), suggesting a role for mutant FGFR3 predominantly in
superficial UC and a role for overexpression of wild-type FGFR3 in
invasive UC. Overexpression of wild-type FGFR1 is also common
in UC of all grades and stages (Tomlinson et al, 2009). Therefore,
FGFR1 and both wild-type and mutant forms of FGFR3 may be
valid therapeutic targets in invasive and non-invasive UC.
The only other tumour type in which FGFR3 has a significant
role is multiple myeloma (MM). The t(4;14) (p16.3;q32) translocation
found in these malignancies results in dysregulated FGFR3
expression in about 15–20% of patients (Chesi et al, 1997, 1998;
Keats et al,2 0 0 3 ;S a n t r aet al, 2003). Approximately 10% of cases
with translocation acquire an activating mutation (Intini et al, 2001),
which contributes to tumour progression (Chesi et al, 2001).
Inhibition of FGFR3 has been effective in preclinical studies of
MM. Small molecule inhibitors and neutralising antibodies induce
cytotoxicity and inhibit proliferation in FGFR3-expressing MM cells
both in vitro and in vivo (Grand et al, 2004; Paterson et al,2 0 0 4 ;
Trudel et al, 2004, 2005, 2006; Chen et al, 2005; Xin et al, 2006).
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sMutant FGFR3 has been validated in vitro as a potential
therapeutic target in bladder cancer, by siRNA knockdown of the
most common mutant forms, S249C and Y375C (Bernard-Pierrot
et al, 2006; Tomlinson et al, 2007b). Targeted inhibition by
neutralising antibodies also results in reduced proliferation of
UC cell lines expressing high levels of wild-type FGFR3 (Gomez-
Roman et al, 2005; Martinez-Torrecuadrada et al, 2005). Recently,
confirmation of an oncogenic role for FGFR3 in UC in vivo has
come from the use of inducible shRNA knockdown to inhibit UC-
derived xenografts and from antibody-based selective inhibition of
FGFR3 in human UC cell line xenografts with either over-
expression of wild-type or mutant FGFR3 (Qing et al, 2009).
Further examination of the effects of FGFR inhibitors in
preclinical models in vivo is required to confirm that dependence
on FGFR1 and both wild-type and mutant FGFR3 in culture
models can be translated into therapeutic efficacy. As normal
urothelial cells express FGFR3 and a potential negative regulatory
effect on their proliferation has been suggested (Tomlinson et al,
2005), examination of the effects of targeted agents on these cells is
required. Here, we have evaluated the in vitro and in vivo effects of
FGFR1 and FGFR3 inhibition in a panel of normal urothelial cells
and bladder tumour cell lines with known FGFR mutation and
expression status using three small molecule inhibitors, with
known activity against FGFRs.
MATERIALS AND METHODS
Cell lines and reagents
Thirteen bladder tumour cell lines were used: FGFR3 mutant cell
lines (97-7, 97-18, 94-10, J82 and MGH-U3), non-mutant cell lines
(RT4, RT112, SW780 and JMSU1) and cell lines that are wild-type
for FGFR3 but have an activating RAS mutation (T24, UM-UC3,
KU-19-19 and HT1197). All lines have been authenticated in our
laboratory by extensive genomic analysis (microsatellite typing,
conventional karyotypic analysis, MFISH, array-based copy
number analysis and mutation analysis) within the last 12 months.
Cells were grown in standard media at 371Ci n5 %C O 2. Normal
human urothelial cells (NHUCs) were derived from urothelium
stripped from human ureters obtained at nephrectomy (Southgate
et al, 1994) and maintained in keratinocyte growth medium
supplemented with epidermal growth factor and bovine pituitary
extract (PromoCell, Sickingenstr, Germany). Two lines of telomerase-
immortalised NHUC (TERT-NHUC) were also used (Chapman
et al, 2006). For FGF2 stimulation experiments cells were treated
with 5ngml
–1 recombinant human FGF2 and 10mgml
–1 heparin
(R&D Systems Europe Ltd, Abingdon, UK).
Kinase assays
The IC50 values for inhibition of FGFR1 and FGFR3 by PD173074
(Sigma, Poole, Dorset, UK), TKI-258 (Selleck Chemicals, London,
ON, Canada) and SU5402 (Calbiochem, supplied by Merck
Chemicals, Nottingham, UK) were determined using a FRET-
based in vitro kinase assay (Z’-lyte assay, Invitrogen, Paisley, UK).
The kinase domains of FGFR1 or FGFR3 were assayed in 50mM
HEPES pH 7.5, 0.01% BRIJ-35, 10mM MgCl2,2 m M MnCl2,1 m M
EGTA, 1mM DTT, with 20mM or 80mM ATP, respectively. The assay
was performed in triplicate in 384-well plates according to the
manufacturer’s instructions.
Adherent and viable cell counts
Cells were plated in six-well plates and adherent cells counted
using a Z2 Coulter Particle Counter and Size analyser (Beckman
Coulter, High Wycombe, Buckinghamshire, UK). Viable cells were
stained using the Guava PCA-96 ViaCount Flex Reagent and
analysed on the Guava Easycyte Desktop Flow Cytometry System
(Guava Technologies, Stamford, Lincolnshire, UK).
Cell viability assay
Cell viability was assessed by 3-(4,5-dimethylthiazol)-2,5-diphenyl
tetrazolium (MTT) assay. In all, 3000 cells per well were plated in
96-well plates in quadruplicate and allowed to attach for 24h
before addition of inhibitor. Medium was replenished with fresh
drug after 48h and the MTT assay performed 72h later. In total,
10ml of 5mgml
–1MTT solution was added to the medium for 4h,
the medium was removed, the precipitate dissolved in DMSO and
absorbance read at 540nm.
Cell cycle and apoptosis analysis
Cell cycle distribution of cells cultured with 500nM PD173074,
500nM TKI-258 or DMSO was evaluated by flow cytometry. Cells
were harvested, fixed overnight in 70% ethanol at 41C, rehydrated
by addition of 10ml phosphate-buffered saline (pH 7.4) and
centrifuged at 450 g for 10min. The pellet was resuspended in
propidium iodide/RNAse mix (Beckman Coulter) and incubated in
the dark at 371C for 30min before analysis on the Guava Easycyte
Desktop Flow Cytometry System. For apoptosis analysis cells were
stained using a Guava-96 Nexin Kit.
Western blotting and immunoprecipitation
Cells were lysed in RIPAE buffer (1% Triton X-100, 1mmoll
–1
EDTA, 0.1% SDS, 0.5% sodium deoxycholate, 10% glycerol, and
protease inhibitor cocktail (Sigma) in PBS) and lysates cleared by
centrifugation at 12700 g at 41C. Protein concentrations were
determined using the bicinchonic acid assay (Thermo Fisher
Scientific, Runcorn, Cheshire, UK). Western blotting and immuno-
precipitation was carried out as described previously (Tomlinson
et al, 2009). FGFR3 was immunoprecipitated using an FGFR3
antibody recognising the extracellular domain (F3922, Sigma).
Antibodies used for western blotting were anti-phospho-ERK1/2,
anti-ERK1/2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
FGFR3 B9 (Autogen Bioclear, Calne, Wiltshire, UK), 4G10 anti-
phosphotyrosine (Cell Signalling Technology, Danvers, MA, USA)
and anti-tubulin alpha (MorphoSys UK Ltd, Kidlington, UK).
Proteins were visualised with chemiluminescence (ECL Plus Kit,
Amersham Biosciences, Little Chalfront, Buckinghamshire, UK).
Blots were stripped in 50mmoll
–1Tris (pH 7.5), 10moll
–1urea at
551C for 30min before re-probing.
Animals
Male Balb/c immunodeficient nude mice (Harlan, Loughborough,
UK) aged 6–8 weeks were used. Mice received Harlan 2018 diet
(Harlan) and water ad libitum. Mice were kept in cages in an air-
conditioned room with regular alternating cycles of light and
darkness. All animal procedures were carried out under a project
licence issued by the UK Home Office and UKCCCR guidelines
(Workman et al, 1998) were followed throughout.
Xenografts were established by subcutaneous inoculation of
MGH-U3, SW780 or RT112 cells. Tumours were excised from a
donor animal, cut into fragments of approximately 2mm
3 and
single fragments implanted into the left abdominal flanks of
recipient mice under brief general anaesthesia using a trocar. Once
the tumours could be accurately measured (mean tumour volume
of 32mm
3), mice were allocated into groups of eight (for each
tumour type and condition) by restricted randomisation to keep
group mean tumour size variation to a minimum and treatment
was commenced. Groups consisted of an untreated control group
and a PD173074-treated group. PD173074 was administered
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 1 per day on days 0–3 (all tumour
types), and days 6–9 (MGH-U3 only).
The effects of therapy were assessed by two-dimensional caliper
measurement. Tumour volumes were calculated using the formula
D d
2 p/6 where D is the larger and d is the smaller diameter of
the tumour. Tumour volume was normalised to the volume on
day 0. Statistical significance was assessed by Mann–Whitney
U-test. A P-value of o0.05 was considered statistically significant.
Immunohistochemistry
Tumours were formalin-fixed and embedded in paraffin wax.
Sections (4mm) were stained with haematoxylin and eosin. Antigen
retrieval was achieved by boiling with citric acid buffer (10mM
citric acid; pH 6; BDH) for 12min. The proliferation-associated
Ki-67 protein was used to identify proliferative cell populations,
using mouse anti-human Ki-67 antibody (Dako, Produktionsvej,
Denmark) at a 1:100 dilution. Ki-67 staining was detected
using streptavidin AB (Dako) and 3,3-diaminobenzidine (Dako).
Sections were counterstained with Mayer’s haematoxylin. Sections
were observed by light microscopy (Zeiss Axioplan; Carl Zeiss UK,
Welwyn Garden City, Hertfordshire, UK). Cells were defined as
proliferative when nuclear brown staining was observed. The
terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labelling (TUNEL) assay (ApopTag Plus Peroxidase In situ
Apoptosis Detection Kit; Millipore, Watford, Hertfordshire, UK)
was used for detection and quantitation of apoptosis at the single-
cell level, labelling DNA strand breaks. Cells were defined as
apoptotic (TUNEL-positive) if nuclear localised brown staining
was observed. Proliferation and apoptotic indices were scored as
the percentage of positive cells in four fields of view from three
different sections from the same tumour (original magnification
 200). Two to three tumours from each tumour type and
condition were analysed in this way.
RESULTS
PD173074, TKI-258 and SU5402 inhibit FGFR3
phosphorylation and downstream signalling
Numerous inhibitors of FGFR activation have been identified.
Here, we assessed two FGFR-selective inhibitors, PD173074
(Mohammadi et al, 1998) and SU5402 (Mohammadi et al, 1997)
and a broad-spectrum tyrosine kinase inhibitor, TKI-258, with
known activity against FGFRs (Lee et al, 2005; Lopes de Menezes
et al, 2005; Trudel et al, 2005). Their reported activity against
receptor tyrosine kinases is shown in Supplementary Table 1. We
confirmed the effect on FGFR3 and FGFR1 kinase activity using an
in vitro kinase assay. All three compounds caused a dose-dependent
reduction in kinase activity (Supplementary Figure 1). RT112 cells
show constitutive activation of FGFR3 and were used to assess the
effects of PD173074, SU5402 and TKI-258 on FGFR3 phosphoryla-
tion and downstream signalling (Figure 1B and C). A time-course of
treatment with PD173074 showed a rapid and sustained inactivation
of FGFR3 (Figure 1B). After 2h of treatment, all inhibitors showed
profound inhibition of FGFR3 phosphorylation. Recently, we have
shown that FGFR3 activates the MAPK pathway in normal urothelial
cells (di Martino et al, 2009). Thus, the effect of treatment on
phosphorylation of ERK was assessed and all three drugs were
found to reduce ERK activation (Figure 1C). In addition, PD173074
was found to block both FGF-induced and constitutive ERK
phosphorylation in 94-10 tumour cells, confirming that PD173074
prevents FGFR-induced ERK activation and is not acting by some
other mechanism (Figure 1A).
Effects of inhibitors on proliferation and viability of
bladder tumour cells
We assessed the effect of the inhibitors on a panel of bladder
tumour cell lines with known FGFR3 and RAS mutation
status (Jebar et al, 2005, unpublished data) (Table 1). We also
determined the transcript levels of FGFRs 1–4 in these cell lines.
Expression of FGFRs 2 and 4 was extremely low in all lines (data
not shown) but highly variable levels of FGFR1 and FGFR3
transcripts (a range of 5–6 logs) were detected (Supplementary
Figure 2). Cells were cultured with a range of concentrations
of each inhibitor for 5 days (0–2000nM PD173074; 0–1000nM
TKI-258; 0–50mM SU5402). Responses were measured by changes
in cell number, shown here for PD173074 (Figure 1D). A dose-
dependent reduction in cell number was observed. Cell viability
analysis by MTT assay gave similar results. Dose-response curves
were created for all cell lines and all three inhibitors (data not
shown) and were used to determine IC50 values (Table 1). All three
compounds inhibited proliferation and viability of three of the five
FGFR3 mutant and all four FGFR3 wild-type cell lines. PD173074
and TKI-258 were most potent, with IC50 values in the nanomolar
range, whereas micromolar concentrations of SU5402 were
required to achieve the same effect.
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Figure 1 The effect of PD173074 on FGFR3 phosphorylation and proliferation of FGFR3-expressing bladder tumour cell lines. (A) 94-10 cells, expressing
FGFR1, were stimulated with heparin (10mgml
–1) with or without FGF2 (5ngml
–1) for 15min in the presence or absence of PD173074 (500nM;
pretreated for 1h). Cells were lysed, immunoblotted for phospho-ERK and reprobed for tubulin as a loading control. (B) RT112 cells were exposed to
PD173074 (PD) (500nM) for 0–24h, TKI-258 (TK) (500nM) or SU5402 (SU) (5mM) for 1h. Cells were lysed, FGFR3 was immunoprecipitated
(immunoprecipitated, IP) and blots (immunoblot, IB) were probed for phospho-tyrosine and reprobed for FGFR3 or (C) probed for phospho-ERK and
reprobed for total ERK. (D) Cells were exposed to 0–2000nM PD173074 for 5 days and the effects analysed by cell counts. Values are represented as a
percentage of the untreated control (100%) and represent mean±1 s.d.
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expression levels. FGFR3-mutant cell lines that were totally
unresponsive to treatment (97-18 and 94-10, which exhibited high
IC50 values for all compounds; Table 1) expressed little or no
FGFR3 (see Supplementary Figure 2 for expression levels) and may
therefore no longer depend on its activity. One of the responsive
cell lines, JMSU1, which does not express FGFR3, overexpresses
FGFR1 and we have shown previously that siRNA-mediated
knockdown of FGFR1 inhibits proliferation of these cells
(Tomlinson et al, 2009). J82, also a non-expresser of FGFR3,
showed only a small response (IC50 for PD173074 of 1400nM).
These cells express FGFR1, albeit at lower levels than JMSU1
(Supplementary Figure 2). The only other cell lines in this panel
that express high levels of FGFR1 are the RAS mutant cell lines
UM-UC3 and HT1197. As activating mutations of RAS genes and
FGFR3 are mutually exclusive events in UC and are thought to
activate the same signalling pathways (Jebar et al, 2005), a RAS
mutation may confer resistance to FGFR inhibition. Indeed, all
four cell lines with an activating RAS mutation were unaffected by
PD170374 or SU5402 treatment and we have shown previously that
siRNA-mediated knockdown of FGFR1 in UM-UC3 has no effect
on proliferation (Tomlinson et al, 2009). PD173074 and SU5402
had no effect on the normal TERT-NHUC control cells. TKI-258
had some inhibitory activity on these controls and the RAS mutant
tumour control cell line HT1197, which may reflect the multi-
targeted nature of this inhibitor.
Despite profound inhibition of cell proliferation in some cell
lines, total cell-kill was not achieved and there was always a small
population of viable cells remaining after treatment. To test
whether these surviving cells represent a sub-population of
resistant cells, we compared the response of previously untreated
RT112 cells with those that had been previously exposed to drugs
(Supplementary Figure 3). Almost identical responses were
observed, demonstrating that a resistant population was not
present. Owing to the presence of viable cells following treatment
at all doses, continuous exposure to all compounds was required to
elicit and maintain a response.
Growth inhibition is associated with cell cycle arrest and
apoptosis
As PD173074 and TKI-258 were the most potent compounds, with
nanomolar IC50 values, these were used for further mechanistic
studies. To examine whether responses in FGFR3-expressing cells
were mediated by cytostatic or cytotoxic effects, responsive cells
(RT112, RT4, SW780, MGH-U3 and 97-7) were analysed for cell
cycle distribution and apoptosis. A significant increase in the
proportion of cells in G1 accompanied by a decrease in S and G2/M
phases was observed in PD173074- and TKI-258-treated RT112,
RT4, MGH-U3 and 97-7 cells after 24-h exposure (Figure 2A). This
effect was more pronounced with PD170374 treatment. SW780
showed no significant change in cell cycle distribution. SW780,
RT4 and MGH-U3 showed an increased apoptotic index after 2–5
days treatment with PD173074 or TKI-258 (Figure 2B). There was
no change in the proportion of apoptotic cells in any other cell
lines over a 5-day time-course.
PD173074 delays tumour growth in vivo
We selected PD173074 for in vivo assessment as it was the most
potent and selective compound, with the lowest IC50 values and
the most pronounced cell cycle and apoptotic effects in vitro.
We tested efficacy on pre-established subcutaneous xenografts of
MGH-U3, which contains Y375C-FGFR3, and RT112 and SW780
both of which are non-mutant but have upregulated expression of
FGFR3 (Figure 3). No evidence of significant toxicity was seen in
the treated animals. Treatment significantly delayed tumour
growth for all cell lines. Tumours were retrieved and fixed
following the final PD170374 treatment and sections stained for
Ki-67 and TUNEL to assess effects on proliferation and apoptosis
respectively. Decreased proliferative index (Figure 3) but no
change in apoptotic index were found in all three cell lines
(Supplementary Figure 4). This suggests that FGFR3 inhibition
induces a cytostatic response in vivo.
DISCUSSION
It is well documented that activating mutations of FGFR3 are
strongly associated with superficial UC (Cappellen et al, 1999;
Billerey et al, 2001; Sibley et al, 2001b). More recently, over-
expression of wild-type FGFR3 has also been found in UC,
particularly in tumours of high grade and stage (Tomlinson et al,
2007a). FGFR3-targeted therapies, small molecule inhibitors and
neutralising antibodies, have been used successfully in MM to
inhibit the proliferation of cell lines in vitro and in vivo, inducing
cell cycle arrest, apoptosis and differentiation (Grand et al, 2004;
Paterson et al, 2004; Chen et al, 2005; Trudel et al, 2005, 2006;
Table 1 IC50 values for PD173074, TKI-258 and SU5402 following 5-day treatment of bladder tumour cell lines and normal urothelial cells
IC50 (nM)
Cell line type Cell line FGFR3 status/expression level PD173074 TKI-258 SU5402
Normal controls (WT FGFR3) NHUC WT 42000 2000 450000
TERT-NHUC B WT 42000 900 50000
TERT-NHUC D WT 42000 650 —
Tumour lines (WT FGFR3+mutant RAS) UM-UC3 WT 42000 42000 450000
T24 WT 42000 42000 450000
KU-19-19 WT 42000 42000 450000
HT1197 WT 42000 1000 445000
Tumour lines (WT FGFR3) SW780 WT overexpressed 50 450 6000
RT112 WT overexpressed 15 200 6000
RT4 WT overexpressed 5 100 2000
JMSU1 WT low expressionþFGFR1 overexpressed 50 250 40000
Tumour lines (Mutant FGFR3) J82 K652E low expressionþFGFR1 overexpressed 1400 1000 45000
MGH-U3 Y375C overexpressed o50 o50 6000
97-7 S249C overexpressed 1000 800 25000
94-10 S249C low expression 42000 42000 —
97-18 S249C low expression 42000 42000 —
Abbreviations: NHUC¼normal human urothelial cell; TERT-NHUC¼telomerase-immortalised NHUC.
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Figure 2 Effect of exposure to PD173074 or TKI-258 on cell cycle distribution and apoptosis. (A) Cells were exposed to PD173074 or TKI-258 (500nM)
for 24h. Cell cycle profile was analysed using the Guava Easycyte Plus flow cytometry system. ANOVA, *Po0.05. Data are representative of three
independent experiments. (B) Effect of PD173074 on apoptosis. Cells were exposed to PD1703074 (500nM) for 6 days and were analysed for apoptosis
using the Guava Nexin assay. 7-AAD, 7-amino-actinomycin-D. Plots are representative of three independent experiments.
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sXin et al, 2006; Qing et al, 2009). Several studies have assessed the
most common FGFR3 mutations, S249C and Y375C, as therapeutic
targets in UC cell lines (Bernard-Pierrot et al, 2006; Tomlinson
et al, 2007b; Miyake et al, 2009; Qing et al, 2009) and have shown
that suppression of FGFR3 activity results in inhibition of
proliferation in vitro. The in vivo potential of FGFR3-targeted
therapies in UC has also been assessed in two recent studies using
xenografted human UC cell lines (Miyake et al, 2009; Qing et al,
2009). Qing et al (2009) used shRNA knockdown and a newly
developed antibody that prevents both ligand binding and receptor
dimerisation and showed inhibition of RT112 xenograft tumour
growth. Miyake et al (2009) used two different FGFR3-mutant
cell lines (UMUC14, MGH-U3), both of which showed growth
delay when treated with PD173074. However, the effects of
FGFR inhibitors have not been tested on FGFR1-dependent
urothelial cells.
Using small molecule inhibitors, we have extended these
findings using a range of both normal and UC-derived cell lines
in vitro and UC xenografts in vivo. Importantly, there was an
encouraging differential between the sensitivities of NHUCs and
bladder tumour cell lines. Normal human urothelial cells and
TERT-NHUC were unresponsive to treatment with high doses of
inhibitors, demonstrating that these cells are not dependent on
FGFR signalling for survival and predicting minimal toxicity to
normal urothelial cells in vivo. This may be of particular
importance if high levels of inhibitors are delivered intravesically
in the future.
The effects of the inhibitors were related to FGFR3 expression
levels. Thus, cell lines that express only low levels of mutant
receptor were unresponsive to treatment, whereas cell lines that
overexpress wild-type or mutant FGFR3 were highly sensitive to
treatment. Cell lines that were unresponsive to FGFR inhibition
may no longer depend on FGFR3, despite the presence of a
mutation. Indeed, we have found previously that 15% of tumours
with an FGFR3 mutation do not show upregulated protein
expression (Tomlinson et al, 2007a). This may represent a subset
for whom FGFR-targeted therapy is inappropriate.
As all three inhibitors have activity against all FGF receptors,
inhibition of other FGFRs may have contributed to a response.
Recently, FGFR1 has been identified as a potential therapeutic
target that drives proliferation and cell survival in UC (Tomlinson
et al, 2009). We showed that the cell line JMSU1 that expresses
high levels of FGFR1 was sensitive to treatment. The smaller
response measured in J82 could be also related to its moderate
expression of FGFR1. We previously showed that shRNA knock-
down of FGFR1 in JMSU1 results in inhibition of proliferation,
indicating that these cells are highly dependent on FGFR1 and
may exhibit an ‘oncogene addiction’ to this receptor (Tomlinson
et al, 2009).
All three small molecule inhibitors have some activity against
other receptor tyrosine kinases. Therefore, we cannot rule out the
possibility that inhibition of other proteins may have contributed
to their response. However, as similar trends were seen with all
three inhibitors, each with different selectivity profiles, and
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Figure 3 Effect of PD173074 on the growth of subcutaneous xenografts. Xenografts were created by inoculating with MGH-U3, RT112 or SW780
bladder tumour fragments (2mm
3 fragments). (A) PD173074 (20mgkg
–1) was administered by intraperitoneal (i.p.) injection, indicated by black arrows.
Tumours were measured at least three times a week and relative tumour volume calculated (*Po0.05; ANOVA). (B) Tumours were retrieved following
the final dose of PD170374, fixed and stained for Ki-67 and proliferative index calculated. Bar¼50mm.
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in bladder cancer, using similar or more specific means of FGFR3
inhibition, we can be reasonably confident that responses are due
to FGFR inhibition rather than contribution from other kinases.
Cell lines that harbour an activating RAS mutation were
included in the panel as controls, as these are predicted to be
independent of FGFR signalling. FGFR3 and RAS mutations are
mutually exclusive events in UC and in MM and are thought to
provide alternative means to activate the same pathway (Plowright
et al, 2000; Jebar et al, 2005). Similarly, MM cell lines with an
activating RAS mutation have been shown to be resistant to FGFR3
inhibition. The differential responses of the bladder tumour cell
lines may therefore reflect the distinct genetic make-up and FGFR3
dependence of individual tumours. Clinically, FGFR-targeted
therapies are likely to be suitable only for patients whose tumours
are still driven by FGFR3 and/or FGFR1 kinase activity. Our
finding of resistance to targeted agents in the presence of FGFR3
mutation underscores the need to use biomarkers of FGFR
dependence rather than mutation status when selecting patients
for therapy in the future. Our present findings indicate that
upregulated expression with or without mutation may be a useful
indicator.
In vitro analysis showed that FGFR3 inhibition by PD173074 and
TKI-258 was associated with cell cycle arrest, with evidence of
apoptosis in some cell lines. The molecular basis for this
differential response is not known but ability to induce apoptosis
may not be related solely to p53 status as the highly sensitive cell
lines RT112 and RT4, only one of which showed an apoptotic
response, are both known to retain wild-type TP53.
PD173074 halted the growth of human bladder tumour
xenografts derived from cell lines that overexpress wild-type
(RT112 and SW780) or Y375C-mutant FGFR3 (MGH-U3). In all
cases, tumour growth resumed following withdrawal of treatment.
PD173074 treatment in vivo was associated with cell cycle arrest as
demonstrated by a decreased Ki-67 staining, but there was no
evidence of apoptosis. Tumours regained their proliferative
capacity following withdrawal of treatment both in vitro and
in vivo and there was no change in proliferative or apoptotic
indices after withdrawal of treatment. As tumour regression was
not observed and PD173074 acted in a cytostatic rather than a
cytotoxic manner it will be necessary to investigate how FGFR-
targeted therapies can cooperate with standard treatments or other
targeted agents.
Despite successfully demonstrating an in vivo effect of FGFR3
inhibition in three UC-derived xenografts, few UC cell lines are
tumorigenic in immunocompromised mice. Improved in vivo
models are urgently required to test the in vivo effect of FGFR
inhibition in other cell lines, particularly FGFR3 mutant cell lines.
In conclusion, we have validated wild-type and mutant FGFR3
and WT FGFR1 as valid therapeutic targets for both muscle-
invasive and superficial UC. Development of FGFR-targeted
therapy (FGFR3 and/or FGFR1) for clinical use is therefore
justified, with a possible future role as a ‘maintenance’ treatment
following other modalities, such as surgery, cytotoxic drugs or
radiation. Additional investigations are required to determine
suitable predictive biomarkers to identify subgroups of patients for
whom such therapies may be beneficial, for example according to
FGFR1/3 expression levels and FGFR3 and RAS mutation status.
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